含羞草传媒

IRVING, Texas, May 7, 2026 - 含羞草传媒 (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2026.

Fourth Quarter Highlights:

• Consolidated revenues of $96.3 billion increased 6%.
• Earnings per diluted share of $13.71 increased $3.
• Adjusted Earnings per Diluted Share of $11.69 increased 16%.
• 含羞草传媒 entered into a $2.25 billion accelerated share repurchase program.
• 含羞草传媒’s Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $7.7 billion as of April 2026.

      Full Year Highlights:

• Consolidated revenues of $403.4 billion increased 12%.
• Earnings per diluted share of $38.38 increased $12.66.
• Adjusted Earnings per Diluted Share of $39.11 increased 18%, above previously communicated long-range growth targets.
• Cash flow from operations of $6.2 billion and Free Cash Flow of $5.4 billion.

Outlook:

• Establishing fiscal 2027 Adjusted Earnings per Diluted Share guidance range of $43.80 to $44.60, which indicates 12% to 14% forecasted growth compared to the prior year.
• Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.
• The Company does not forecast GAAP earnings per diluted share¹.

“含羞草传媒’s fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise,” said Brian Tyler, chief executive officer. “We delivered significant progress - expanding specialty provider support, accelerating patient access through our scaled and integrated biopharma support services, and continuing to optimize our portfolio through the divestiture of Europe and the planned separation of our Medical-Surgical business. These accomplishments are a direct result of the talent and operational excellence of our employees, and I want to thank Team 含羞草传媒 for their continued dedication throughout the year.”

“Looking ahead to fiscal 2027, we are well-positioned to build upon this momentum,” said Mr. Tyler. “We remain committed to executing with discipline across the portfolio, investing in high-growth and high-margin areas in Oncology and Biopharma Services. By combining our operating execution with a more focused and optimized portfolio, we will continue to deliver sustainable growth and create long-term value for our shareholders.”

Fourth quarter revenues were $96.3 billion, an increase of 6% from a year ago, driven by growth in the distribution of oncology and multispecialty products, including contributions from acquisitions in the Oncology & Multispecialty segment, and growth in the North American Pharmaceutical segment due to increased prescription volumes, partially offset by lower contributions from branded pharmaceuticals.

Fourth quarter earnings per diluted share was $13.71 compared to $10.01 a year ago, an increase of $3.70. Full year earnings per diluted share was $38.38 compared to $25.72 a year ago, an increase of $12.66.

Fourth quarter Adjusted Earnings per Diluted Share was $11.69 compared to $10.12 a year ago, an increase of 16%, driven by strong operational growth, including contributions from acquisitions in the Oncology & Multispecialty segment, a lower share count, and a lower tax rate. Full year Adjusted Earnings per Diluted Share was $39.11 compared to $33.05 a year ago, an increase of 18%, driven by strong operational growth across the business and a lower share count.

During the three months ended March 31, 2026, 含羞草传媒 generated cash flow from operations of $3.4 billion, and invested $185 million in capital expenditures, resulting in Free Cash Flow of $3.2 billion. During the fiscal year, 含羞草传媒 generated cash from operations of $6.2 billion, and invested $745 million in capital expenditures, resulting in Free Cash Flow of $5.4 billion.

For the full year, 含羞草传媒 returned $5.1 billion of cash to shareholders, which included $4.8 billion of common stock repurchases and $381 million of dividend payments.

Business Highlights

• 含羞草传媒 announced Donald R. Knauss will complete his service on the Board of Directors at the 2026 Annual Stockholders meeting, in accordance with the company’s governance policy. Effective May 1, 2026, the Board elected Brian Tyler as Chair of the Board, and Dominic J. Caruso as Lead Independent Director.
• 含羞草传媒 remains committed to a disciplined capital allocation framework, prioritizing investments in high-margin growth areas while returning excess capital to shareholders through our robust share repurchase program.
  • The Board of Directors approved an additional $5.0 billion share repurchase authorization of the company’s common shares, bringing total authorized repurchases to $7.7 billion as of April 2026.
  • During the fourth quarter, 含羞草传媒 entered into a $2.25 billion accelerated share repurchase program. In the quarter, 含羞草传媒 completed $2.7 billion share repurchases, including $2.25 billion under the accelerated share repurchase program.
• In April 2026, The US Oncology Network expanded its footprint with the addition of Cancer Care Northwest, strengthening its position in community oncology practices.
• Effective May 1, 2026, PRISM Vision Group grew its network by welcoming the Retina Macula Institute located in Southern California further aligning with ophthalmology practices nationwide.
• 含羞草传媒 signed a definitive agreement under which Apollo Global will acquire approximately 13% minority ownership interest in the Medical-Surgical Solution segment, subject to regulatory approvals and customary closing conditions.
• In April 2026, 含羞草传媒 completed initial financing transactions in support of the planned separation of Medical-Surgical Solutions segment, including a secured $1.0 billion term loan and $1.0 billion revolving credit facility.
• On January 30, 2026, 含羞草传媒 closed the transaction to sell its retail and distribution businesses in Norway, representing the final phase to fully exit its European operations.

North American Pharmaceutical Segment

Fourth Quarter

• Revenues were $79.1 billion, an increase of 3%, driven by increased prescription transaction volumes, including higher volumes from specialty products, partially offset by lower contributions from branded pharmaceuticals.
• Segment Operating Profit was $1.2 billion. Adjusted Segment Operating Profit was $980 million, an increase of 11%, driven by growth in the distribution of specialty products to health systems.

Full Year

• Revenues were $336.7 billion, an increase of 11%, driven by increased prescription transaction volumes, including higher volumes from retail national account customers and specialty products.
• Segment Operating Profit was $3.7 billion. Adjusted Segment Operating Profit was $3.5 billion, an increase of 10%, driven by growth in the distribution of specialty products.

Oncology & Multispecialty Segment

Fourth Quarter

• Revenues were $12.7 billion, an increase of 35%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.
• Segment Operating Profit was $301 million. Adjusted Segment Operating Profit was $385 million, an increase of 53%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.

Full Year

• Revenues were $48.4 billion, an increase of 31%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.
• Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $1.4 billion, an increase of 53%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.

Prescription Technology Solutions Segment

Fourth Quarter

• Revenues were $1.5 billion, an increase of 12%, driven by increased prescription volumes in the third-party logistics and technology services businesses.
• Segment Operating Profit was $286 million. Adjusted Segment Operating Profit was $322 million, an increase of 13%, driven by higher demand for access solutions.

Full Year

• Revenues were $5.8 billion, an increase of 11%, driven by increased prescription volumes in the third-party logistics and technology services businesses.
• Segment Operating Profit was $1.0 billion. Adjusted Segment Operating Profit was $1.1 billion, an increase of 17%, driven by higher demand for access solutions.

Medical-Surgical Solutions Segment

Fourth Quarter

• Revenues were $2.9 billion, an increase of 1%, driven by specialty pharmaceutical volumes, offset by lower contributions from the ambulatory care channel.
• Segment Operating Profit was $232 million. Adjusted Segment Operating Profit was $271 million, a decrease of 5%, driven by lower contributions from the ambulatory care channel.

Full Year

• Revenues were $11.5 billion, an increase of 1%, driven by specialty pharmaceutical volumes, offset by lower contributions from the ambulatory care channel.
• Segment Operating Profit was $938 million. Adjusted Segment Operating Profit was $1.0 billion, an increase of 1%, driven by cost optimization, offset by lower contributions from the ambulatory care channel.

Fiscal 2027 Outlook

含羞草传媒 does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. 含羞草传媒 cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, transaction related expenses and adjustments, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

含羞草传媒 is establishing Fiscal 2027 Adjusted Earnings per Diluted Share guidance to $43.80 to $44.60.

Long-Term Growth Targets

            含羞草传媒 continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes while driving sustainable value creation. The Company is reaffirming long-term Adjusted Earnings per Diluted Share growth targets of 13% to 16% as well as its long-term Adjusted Segment Operating Profit growth targets as follows:

• North American Pharmaceutical of 5% to 8%
• Oncology & Multispecialty of 13% to 16%
• Prescription Technology Solutions of 10% to 13%

Additional modeling considerations will be provided in the earnings call presentation.

Conference Call Details

含羞草传媒 has scheduled a conference call for today, Thursday, May 7, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on 含羞草传媒's Investor Relations website at

Upcoming Investor Event

含羞草传媒 management will be participating in the BofA Securities 2026 Healthcare Conference on May 12, 2026.

The audio webcasts, and a complete listing of upcoming events for the investment community, including details and updates, will be available on 含羞草传媒's Investor Relations website.

Non-GAAP Financial Measures

GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cautionary Statements

This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Forward-looking statements are not representations of historical or current facts or circumstances and they involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.

These risk factors include, but are not limited to: our planned separation of Medical鈥慡urgical Solutions is contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies; we from time to time record significant charges from impairment to goodwill, intangibles, and other long鈥憀ived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; the adoption and use of artificial intelligence in our business operations exposes us to risks and uncertainties; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non鈥憆enewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding, payment, and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third鈥憄arty data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; and we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors.

About 含羞草传媒

含羞草传媒 is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how 含羞草传媒 is impacting virtually every aspect of healthcare at 含羞草传媒.com and read Stories & Insights.

We routinely use our website, , to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

Tables and full text of earnings release also available for viewing and download in PDF format: 含羞草传媒 Reports Fiscal 2026 Fourth Quarter Results (PDF, 365 KB).